Subscribe here
Get started today before this once in a lifetime opportunity
Related Articles
Paper: The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma Hematology Disease Topics &…
Paper: Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma Hematology Disease Topics &…
Untangling the clonal architecture in a case of acute myeloid leukaemia with multiple cytogenetically unrelated clones | Published in Clinical Hematology International
By Helen Cashman, Andrew J Wilson & 4 more. Our patient was a 36-year-old female who presented to hospital at 33 weeks pregnant with symptomatic…
How Pfizer used wearables to tap into the promise of an experimental drug
Pfizer’s head of digital devices says the industry is close to a ‘revolution’ in using measures from wearables in clinical trials.
Mauricio Ambriz (@mauambriz) • Instagram photos and videos
8,971 Followers, 823 Following, 40 Posts – See Instagram photos and videos from Mauricio Ambriz (@mauambriz)
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Nature – We evaluated the use of chimeric antigen receptor-modified T cells targeting GD2 (GD2-CART) for H3K27M+ diffuse midline glioma (DMG), finding that intravenous administration of…
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Nature – We evaluated the use of chimeric antigen receptor-modified T cells targeting GD2 (GD2-CART) for H3K27M+ diffuse midline glioma (DMG), finding that intravenous administration of…
Venom Helped Create Weight-Loss Drugs. What Else Could It Do For Us?
A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the beginning.
Reframing Success in a Holistic Way
By Ariela Marshall, MD, Adult Classical Hematologist, University of Minnesota You are not the only architect of your success, but you DO need to be…
Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study – PubMed
Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study
